Clinical Trial

Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The main purpose of this study is to compare the bioavailability of 3 different formulations of LY4100511 and if the use of a proton pump inhibitor (PPI) alters the bioavailability of the 3 different formulations.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-07 -> 2026-08 2026-07-17
minor Completion pushed: 2026-07 -> 2026-08 2026-07-17
Trial Details
NCT Number NCT06916143
Lead Sponsor Eli Lilly and Company
Conditions Healthy Participants
Enrollment 48 participants
Start Date 2025-04-08
Primary Completion 2026-08 (estimated)
Study Completion 2026-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-16